financetom
Business
financetom
/
Business
/
Tempur Sealy's deal to buy Mattress Firm aims to 'eliminate' competition, document shows
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Tempur Sealy's deal to buy Mattress Firm aims to 'eliminate' competition, document shows
Aug 16, 2024 3:17 PM

Aug 16 (Reuters) - Mattress maker Tempur Sealy

International's ( TPX ) proposed $4-billion takeover of retailer

Mattress Firm is intended to "eliminate future competition",

according to a document unsealed by a Texas judge.

A May 2022 presentation to the board by the company's CEO

stated that buying Mattress Firm would enable Tempur Sealy ( TPX ) to

"eliminate future competition" and "block future competition",

the papers showed. The presentation did not name the executive.

Scott Thompson has been Tempur Sealy ( TPX ) CEO since 2015, after

shareholders ousted Mark Sarvary.

The document, unsealed on Wednesday, is among submissions by

the U.S. Federal Trade Commission, which sued last month to

block the cash-and-stock deal announced in May 2023.

The FTC expressed concerns about the deal's impact on

competition, higher prices for consumers and potential job

losses for manufacturing workers.

The two companies and the FTC did not immediately respond to

Reuters requests for comment.

Through the deal, Tempur Sealy ( TPX ) seeks to add Mattress Firm's

2,300-plus brick-and-mortar stores. The combined company will

have about 3,000 stores globally, if the deal goes through.

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Quantum computing systems firm D-Wave's Q3 revenue beats
Quantum computing systems firm D-Wave's Q3 revenue beats
Nov 6, 2025
Overview * D-Wave fiscal Q3 revenue grows 100% yr/yr, beating analyst expectations * Company reports highest cash balance in history at $836 mln * Net loss for fiscal Q3 increases due to non-cash warrant liability charges Outlook * Company did not provide specific financial guidance for future periods Result Drivers * REVENUE GROWTH - Co reports 100% yr/yr revenue increase...
Healthcare tech firm CareCloud's Q3 revenue up 9%, beats expectations
Healthcare tech firm CareCloud's Q3 revenue up 9%, beats expectations
Nov 6, 2025
Overview * CareCloud ( CCLD ) Q3 revenue rises 9% yr/yr, beating analyst expectations * Company raises full-year 2025 revenue guidance to $117-$119 mln * CareCloud ( CCLD ) completes Medsphere acquisition, accelerates AI initiatives Outlook * CareCloud ( CCLD ) raises full-year 2025 revenue guidance to $117-$119 mln * Company expects full-year 2025 adjusted EBITDA of $26-$28 mln *...
US FDA expands use of J&J's Caplyta as add-on depression drug
US FDA expands use of J&J's Caplyta as add-on depression drug
Nov 6, 2025
Nov 6 (Reuters) - The U.S. Food and Drug Administration has approved the expanded use of Johnson & Johnson's ( JNJ ) drug Caplyta as an add-on treatment for adults with major depressive disorder, the company said on Thursday. J&J gained access to Caplyta with its $14.6 billion acquisition of neurological drugmaker Intra-Cellular Therapies in January. The FDA's decision marks...
TransAlta Down in U.S. Pre-market trading After Booking Q3 Loss
TransAlta Down in U.S. Pre-market trading After Booking Q3 Loss
Nov 6, 2025
07:30 AM EST, 11/06/2025 (MT Newswires) -- TransAlta's ( TAC ) share price fell 2.7% at last look Thursday in New York Stock Exchange trading as the company swung to an adjusted net loss widened in the third quarter. TransAlta ( TAC ) posted an adjusted net loss of C$8 million, or a loss of $0.02 per share, reversing the...
Copyright 2023-2026 - www.financetom.com All Rights Reserved